Metabolic Disorders Drugs Global Market Report 2018

1
MetadoliÐ Disorder Drugs Glodal Market Report ???8
Including AYti-diadetiÐ drugs AYti-thyroid
drugs Others Hyperparathyroidisw,
Hypopituitarisw, HypoadreYalisw?
Covering SaYofi S.A, Novo Nordisk A/S,
AstraZeYeÐa PlÐ, JohYsoY JohYsoY, MerÐk Co
Fed ???8
2

• Reasons to Purchase
• Outperform competitors using accurate up to date
  demand-side dynamics information.
• Identify growth segments for investment.
• Facilitate decision making on the basis of
  historic and forecast data and the drivers and
  restraints on the market.
• Create regional and country strategies on the
  basis of local data and analysis.
• Stay abreast of the latest customer and market
  research findings
• Benchmark performance against key competitors.
• Develop strategies based on likely future
  developments.
• Utilize the relationships between key data sets
  for superior strategizing.
• Suitable for supporting your internal and
  external presentations with reliable high quality
  data and analysis
• Gain a global perspective on the development of
  the market.
• Report will be updated with the latest data and
  delivered to you within 3-5 working days of order.

Scope Markets Covered Anti-diabetic drugs
Anti-thyroid drugs Others (Hyperparathyroidism,
Hypopituitarism, Hypoadrenalism) Companies
Mentioned Sanofi S.A, Novo Nordisk A/S,
AstraZeneca Plc, Johnson Johnson, Merck
Co Countries Brazil, China, France, Germany,
India, Italy, Japan, Spain, Russia, UK, USA and
Australia. Regions Asia-Pacific, Western Europe,
Eastern Europe, North America, South America,
Middle East And Africa Time series Five years
historic and forecast. Data Ratios of market
size and growth to related markets, GDP,
Expenditure Per Capita, Metabolic Disorder Drugs
Market Indicators Comparison. Data segmentations
Country and regional historic and forecast data,
market share of competitors, market
segments. Sourcing and Referencing Data and
analysis throughout the report is sourced using
end notes.
3
Metabolic Disorder Drugs Market Characteristics

• The metabolic disorders drugs market covers
  medications that are used in the treatment of
  metabolic diseases such as diabetes, thyroid,
  hyperparathyroidism, hypopituitarism, and
  hypoadrenalism. Some of the major drugs used in
  the treatment of metabolic diseases are Insulin,
  Methimazole, and Calcimimetics. The market
  numbers within this briefing are restricted to
  pharmaceutical (drug) treatments and do not cover
  biologic treatments for these conditions which
  are included in a separate briefing.
• The metabolic disorders drugs industry is further
  classified as follows
• Anti-Diabetic drugs companies produce drugs that
  can be used to manage diabetes by stabilizing and
  controlling blood glucose levels in diabetic
  patients. Some of the major anti-diabetic drugs
  include Insulin, Pramlintide (Amylin), GLP-1
  receptor agonists (such as Byetta and Victoza),
  and Oral hypoglycemics (tablets).
• Anti-Thyroid Drugs companies produce drugs that
  can be used for treatment of an overactive
  thyroid (hyperthyroidism) caused by Graves'
  disease. These drugs are also called thionamides
  and some of its major examples include
  Methimazole and Propylthiouracil.
• Other (Hyperparathyroidism, Hypopituitarism,
  Hypoadrenalism) Drugs companies produce drugs for
  the treatment of disorders related to parathyroid
  glands, pituitary glands, and adrenal glands.
  Some of the major examples of hyperparathyroidism,
  hypopituitarism, hypoadrenalism drugs include
  Calcimimetics and Corticosteroids.
• Pharmaceutical companies manufacturing metabolic
  disorders drugs initially involve in drug
  discovery process by

4
Metabolic Disorder Drugs Market Historic Growth

The global metabolic disorder drugs market grew
from X billion in 2013 to X billion in 2017 at
a compound annual growth rate (CAGR) of X. The
chart and table below shows the year-on-year
growth of the global metabolic disorder drugs
market during 2013 2017.
Drivers of the Market
Restraints on the Market
5
Metabolic Disorder Drugs Market Forecast Growth
The global metabolic disorder drugs market is
expected to grow from X billion in 2017 to X
billion in 2021 at a compound annual growth rate
(CAGR) of X. The chart and table below shows the
year-on-year growth of the global metabolic
disorder drugs market during 2017 - 2021.
Drivers of the Market
Restraints on the Market
6
Metabolic Disorder Drugs Market Segmentation
The chart and table below shows the split of the
metabolic disorder drugs market in 2017.
The total market value for metabolic disorder
drugs was X billion in 2017. The markets that
are covered include Anti-diabetic drugs
Anti-thyroid drugs Others (Hyperparathyroidism,
Hypopituitarism, Hypoadrenalism) Anti-diabetic
drugs market was the x largest segment in the
metabolic disorder drugs market with X share of
the market. The market value for the
Anti-diabetic drugs market was x billion in
2017. Anti-thyroid drugs made up around X share
of the market. The market value for
the anti-thyroid drugs was x billion in 2017.
7
Metabolic Disorder Drugs Market Regional And
Country Analysis
The Asia Pacific was the x largest region in the
metabolic disorder drugs market in 2017,
metabolic disorder drugs for X billion or X
market share. North America was the x largest
region in the metabolic disorder drugs accounting
for X billion or X market share. Europe was
the x largest region in the metabolic disorder
drugs accounting for X billion or X market
share.
8
Metabolic Disorder Drugs Market Competitive
Landscape
The leading competitors in the global metabolic
disorder drugs market are Sanofi S.A, Novo
Nordisk A/S, AstraZeneca Plc, Johnson Johnson,
Merck Co. The chart and table below displays
the percentage market share of the top players in
the metabolic disorder drugs market industry.
Company Profile Sanofi S.A
Overview Products and Services Strategy Financial
Performance
9
Novo Nordisk A/S Overview Products and Services
Strategy Financial Performance AstraZeneca
Plc Overview Products and Services
Strategy Financial Performance Johnson
Johnson Overview Products and Services
Strategy Financial Performance Merck Co.
Overview Products and Services Strategy Financial
Performance